Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
– New preclinical findings generated through in vitro testing of sotrovimab againstthe complete pseudo-virus updated to bioRxiv – Data build on promising signal published... | December 7, 2021